Synthetic peptides immunoreactive with hepatitis A virus antibodies
AssigneeCenters for Disease Control
InventorsHoward A. Fields, Yury E. Khudyakov
Life of this patent
Estimating the term…
Abstract
Synthetic peptides immunoreactive with hepatitis A virus (HAV) antibodies are provided. The peptides are useful as laboratory reagents to detect or quantify HAV antibodies in biological samples in clinical or research-based assays and for inducing an immune response to HAV when administered to a human or animal. The peptides contain antigenic epitopes, modified antigenic epitopes or combinations of epitopes of the major structural capsid polypeptides or non-structural polypeptides of HAV and contain one or more molecules of the amino acid glutamine (Q) at the carboxyl end of the peptide, which enhances immunoreactivity and immunogenicity, particularly IgM antibody reactivity.
Claims7
A method for detecting the presence of antibodies against Hepatitis A virus in a subject, comprising contacting antibodies from the subject with one or more synthetic peptides that are immunoreactive with antibodies directed against Hepatitis A virus (HAV), wherein the peptide is at least nine amino acid residues in length to 35 amino acid residues in length with one molecules of the amino acid glutamine at the carboxyl terminal, and detecting binding of the peptides to the antibodies, wherein detecting binding of the peptides to the antibodies indicates the presence of antibodies against Hepatitis A virus in the subject.
A method for detecting acute phase infection of Hepatitis A virus in a subject, comprising contacting antibodies from the subject with one or more synthetic peptides that are immunoreactive with antibodies directed against Hepatitis A virus (HAV), wherein the peptide is at least nine amino acid residues in length to 35 amino acid residues in length with one molecules of the amino acid glutamine at the carboxyl terminal, and detecting binding of the peptide to Igm antibodies against Hepatitis A virus, wherein detecting binding of the peptide to Igm antibodies indicates acute phase infection of Hepatitis A virus in the subject.
A method of enhancing immunoreactivity of a synthetic peptide to an Igm antibody directed against Hepatitis A Virus, comprising synthesizing the peptide with one or more glutamine molecules at the carboxyl terminal of the peptide, wherein the carboxyl terminal glutamine enhances immunoreactivity of the peptide to an Igm antibody directed against Hepatitis A Virus.
Dependencies are inferred from the claim text.